Status: Finalised
First registered on:
22/10/2017
Last updated on:
03/05/2021
1. Study identification
EU PAS Register NumberEUPAS21352
Official titleStudy of utilisation of combined hormonal contraceptives in Europe
Study title acronym
Study typeObservational study
Brief description of the studyThis study has the following objectives
1. To investigate trends in new user (initiators) prescribing
patterns in the two years preceding the relevant
Commission Decision (January 2012 – January 2014)
and in a similar period following the decision (February
2014– December 2015).
2. To investigate switching patterns between products
among prevalent users including reasons for changes
(e.g., reimbursement or regulatory and clinical
guidance).
3. Within Objectives 1 and 2, to examine any changes in
utilisation in groups defined by patient’s clinical and
demographic risk factors for VTE as detailed in the
warnings and contraindications in the European Union
Summary of Product Characteristics (SmPC).
4. To examine any differences in the incidence rates of VTE
between the two periods specified and, in light of the
results for Objective 1-3, to investigate any measurable
association between the observed changes in CHC use
and changes in the VTE incidence rates.
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupDepartment of Clinical Epidemiology
Organisation/affiliationAarhus University / Aarhus University Hospital
Details of (Primary) lead investigator
Title Professor
Last name Sørensen
First name Henrik Toft
Is this study being carried out with the collaboration of a research network?
Yes
Aarhus University Consortium (ad-hoc)
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?3
University College London, Leiden University, the Netherlands
Countries in which this study is being conducted
International study
Denmark
Netherlands
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed23/11/201623/11/2016
Start date of data collection30/11/201730/11/2017
Start date of data analysis
Date of interim report, if expected01/08/201801/08/2018
Date of final study report14/11/201803/12/2018
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding schemeEuropean Medicines Agency100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Ehrenstein
First name Vera
Address line 1Department of Clinical Epidemiology
Address line 2Olof Palmes Alle 43-45
Address line 3
CityAarhus N
Postcode
CountryDenmark
Phone number (incl. country code)45-87167212
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Sørensen
First name Henrik Toft
Address line 1Olof Palmes Allé 43-45
Address line 2
Address line 3
CityAarhus N
Postcode8200
CountryDenmark
Phone number (incl. country code)45-87167212
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)G03 (PROGESTOGENS AND ESTROGENS IN COMBINATION)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Sex
Female
9. Number of subjects
Estimated total number of subjects500000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Data sources not registered with ENCePP
Dutch Foundation for Pharmaceutical Statistics (SFK), Netherlands
Sources of data
Prescription event monitoring
Administrative database, e.g. claims database
Routine primary care electronic patient registry
Pharmacy dispensing records
11. Scope of the study
What is the scope of the study?
Risk assessment
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
1. To investigate trends in new user (initiators) prescribing patterns in the two years preceding the relevant Commission Decision
2. To investigate switching patterns between products among prevalent users
3. To examine changes in users' clinical characteristics
4. To examine differences in VTE einidence rates
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
For each calendar year, we provide
- estimates of the number and proportion of new users of each oral contraceptive type and the number and proportion of switchers (from one type to another or to a different dose)
- estimates of the proportion of each oral contraceptive type and the number of switchers (from one type to another or to a different pill strength) December 2015), we will perform segmented regression analysis.
- number of initiators of each oral contraceptive type and the number of switchers (from one type to another or to a different dose) overall and stratified by age at initiation of CHC, social deprivation , body mass index (BMI) and smoking status.
We will tabulate the estimates of the annual incidence of VTE including 95% confidence intervals for each calender window of the study period.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
Khialani D, Jones ME, Szepligeti SK, et al. Combined hormonal contraceptive use in Europe before and after the European Commission mandated changes in product information. Contracept X 2020;2:100018. doi: 10.1016/j.conx.2020.100018 [published Online First: 2020/06/19]https://www.ncbi.nlm.nih.gov/pubmed/32550533
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Submitted
